Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Investigation of DehydraTECH-CBD’s Potential Therapeutic Value for Diabetes and Defmentia with New Studies

• Lexaria’s Patented DehydraTECH technology improves the bioavailability of pharmaceuticals and therapeutics for a number of developing applications
• Lexaria is set to complete its DEM-A22-1 and DIAB-A22-1 studies on dementia and diabetes, respectively, in January 2023, with analysis and reporting set to follow soon after
• These studies will build on the just-concluded hypertension clinical study whose results were “truly exceptional,” demonstrating a statistically significant lowering of blood pressure in the patient population over multiple weeks
• There is an established link between hypertension and vascular dementia, along with hypertension being twice as frequent in people with diabetes and hypertensive patients being at greater risk of developing diabetes
• The success of these two studies will draw Lexaria closer to tapping into the dementia drug market, which is projected to hit $32.3 billion by 2030, and the diabetes drug market, which is expected to reach $82.92 billion by 2027

Lexaria Bioscience (NASDAQ: LEXX) just announced two notable studies, DEM-A22-1, and DIAB-A22-1, on dementia and diabetes, respectively, scheduled for completion in January 2023. The studies seek a deeper understanding of the company’s patented DehydraTECH(TM)-processed CBD for its potential therapeutic utility against both conditions (https://cnw.fm/5cLyS).

According to John Docherty, Lexaria’s President and Head of Research, these studies will build on the just-concluded hypertension clinical study whose results he referred to as “truly exceptional.”  The study demonstrated a statistically significant lowering of blood pressure in the patient population over multiple weeks, something that, Docherty noted, other entities using other oral CBD formulations have failed to replicate or even evidence.

“The study demonstrated excellent safety and tolerability of DehydraTECH-CBD and no adverse changes in liver enzymes throughout the study, a common concern in CBD dosing. We were also able to show that decreases in blood pressure were similar in participants currently taking standard of care hypertension medications to those not undergoing any concurrent blood pressure treatment,” he noted.

There is an established link between hypertension and vascular dementia. In addition, hypertension is twice as frequent in people with diabetes, and hypertensive patients are at greater risk of developing diabetes. Lexaria looks to draw from the success of its hypertension clinical study to show DehydraTECH-CBD’s potential to offer potential therapeutic utility against these two conditions.

Currently, dementia is ranked as the seventh leading cause of death among all diseases, accounting for 40 out of every 100,000 deaths in the United States (https://cnw.fm/44c6G). It also currently affects seven million Americans and has a significant unmet need that Lexaria hopes to meet. Diabetes, on the other hand, ranks as the eighth leading cause of death in the United States, accounting for 31 out of every 100,000 deaths in the country (https://cnw.fm/5Gfti). Over 37.3 million people, representing 11.3% of the country’s population, live with the condition, yet few viable treatment options are available for them (https://cnw.fm/OHDSl).

CBD has, so far, shown some ability to reduce the incidence of diabetes in mice due to its powerful anti-inflammatory and antioxidant properties. In addition, Lexaria has proven DehydraTECH’s ability to cross the blood-brain barrier effectively. As such, it is optimistic that it will achieve potential treatment for both dementia and diabetes.

“We are excited to investigate whether DehydraTECH-CBD has a potential application in the treatment of dementia and diabetes based on its propensity to cross the blood-brain barrier, the fact that DehydraTECH-CBD lowers human blood pressure, and the fact that CBD is known to have vasodilatory, anti-inflammatory and antioxidant effects,” noted Mr. Docherty.

The two studies will be undertaken by leading third-party testing laboratories in Canada, with analysis and reporting set to follow their scheduled completion in January 2023. Their success will draw Lexaria closer to tapping into the dementia drug market, projected to hit $32.3 billion by 2030, and the diabetes drug market, which is expected to reach $82.92 billion by 2027.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About HempWire

HempWire (HW) is a dedicated information provider focused on (1) aggregating hemp-related news, (2) issuing HempNewsBreaks designed to update investors on the latest developments in the hemp market, (3) enhancing corporate news releases, (4) providing full-service distribution and social media offerings to public and private client-partners and (5) designing and implementing all-inclusive corporate communication solutions. HW is strategically positioned within the rapidly expanding hemp sector with a team of journalists working to help a growing roster of public and private companies reach a wide audience of investors, consumers and members of the media. We leverage a vast network of more than 5,000 key syndication outlets to deliver unparalleled visibility, recognition and content to the hemp industry. HempWire (HW) is where HEMP news, content and information converge.

To receive instant SMS alerts, text HEMPWIRE to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.hempwire.com

Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.hempwire.com/Disclaimer

Do you have a questions or are you interested in working with HW? Ask our Editor

HempWire (HW)
Denver, Colorado
www.hempwire.com
303.498.7722 Office
Editor@HempWire.net

HempWire is part of the InvestorBrandNetwork.